MOUSE

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.

Experts Share 5 eCommerce Brand-Building Business Strategies for More Sales in 2022 [DesignRush QuickSights]

Retrieved on: 
Wednesday, July 6, 2022
People, E-commerce, Acquisition, Creative, Van Nest–Hoff–Vannatta Farmstead, Geoffrion, Marketing, Element, Friends, Industry, FB, Awareness, Automation, INSTALL, Havas, MOUSE, Facebook, Human, Mizrahi Jews, Social media, Online shopping, Sales, Public relations

MIAMI, July 6, 2022 /PRNewswire-PRWeb/ -- With as many as 9.1 million online retailers in the world, as per etailinsights' data, eCommerce is an increasingly crowded sector. The most sure proof way to stand out in this competitive landscape is to turn a business into a strong brand that drives trust and improves customer loyalty.

Key Points: 
  • DesignRush reached out to industry experts to discover the key eCommerce brand-building strategies businesses should use for more sales in 2022.
  • MIAMI, July 6, 2022 /PRNewswire-PRWeb/ -- With as many as 9.1 million online retailers in the world, as per etailinsights' data, eCommerce is an increasingly crowded sector.
  • DesignRush , a B2B marketplace connecting businesses with agencies, leveraged its 13,000-agencies-strong network for quick insights or "QuickSights" on the key eCommerce brand-building strategies businesses should leverage for more sales in 2022.
  • "[It enables] you to speak to your audience with that same tonality on every element of your business that you share.

Canada's First Ever PORTL Hologram Display Kicks Off with Johnnie Walker

Retrieved on: 
Wednesday, December 1, 2021
Non-fungible token, Sport, CEO, Technology, Industry, LCBO, Cadillac, Taste, Holiday, Marketing, Steve Mann (inventor), Toronto Eaton Centre, Education, TIM, Software, 3D, Twitter, DIGITAL, GLOBE, MOUSE, Johnnie Walker, Mark (given name), Culture, Digital, Instagram, Mobile, Spadina Avenue, Online shopping, Video game console, Television

Im pretty sure everyone is going to want a hologram mixologist at home once they see this."

Key Points: 
  • Im pretty sure everyone is going to want a hologram mixologist at home once they see this."
  • MOUSE 3D DIGITAL plans to bring the future forward with innovative PORTL activations across Canada that allow for stronger consumer connections.
  • The activation with Johnnie Walker is the first of many uniquely interactive experiences to be offered to consumers across Canada.
  • The PORTL technology will also be featured at Canadas first hologram fashion show located at Cadillac Fairviews Toronto Eaton Centre on December 3, 2021.